Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence, J Invest Dermatol, vol.133, issue.2, p.37785, 2013. ,
The global state of psoriasis disease epidemiology: a workshop report, Br J Dermatol, vol.177, issue.1, p.47, 2017. ,
Sex-and ageadjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the « OBJECTIFS PEAU » study, J Eur Acad Dermatol Venereol JEADV, 2018. ,
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening, J Am Acad Dermatol, vol.58, issue.6, p.103142, 2008. ,
Brain-skin connection: stress, inflammation and skin aging, Inflamm Allergy Drug Targets, vol.13, issue.3, p.17790, 2014. ,
The neuro-immuno-cutaneous-endocrine network: relationship of mind and skin, Arch Dermatol, vol.134, issue.11, p.14315, 1998. ,
, Encyclo Méd Chir, Psychiatrie, p.2017
Low-grade inflammation predicts persistence of depressive symptoms, Psychopharmacology (Berl), vol.233, issue.9, p.166978, 2016. ,
Alpha-interferon and mental disorders, L'Encephale, vol.27, issue.4, p.30817, 2001. ,
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis, Psychosom Med, vol.71, issue.2, p.17186, 2009. ,
Cumulative meta-analysis of interleukins 6 and 1?, tumour necrosis factor ? and C-reactive protein in patients with major depressive disorder, Brain Behav Immun, vol.49, p.20615, 2015. ,
The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery, Psychoneuroendocrinology, vol.45, p.7786, 2014. ,
The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis, Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol, vol.36, issue.12, p.24529, 2011. ,
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers, JAMA Psychiatry, vol.70, issue.1, p.3141, 2013. ,
Sickness Behavior, and Depression, Neurol Clin, vol.24, issue.3, p.44160, 2006. ,
Psoriasis and Associated Psychiatric Disorders, J Clin Aesthetic Dermatol, vol.9, issue.6, p.3643, 2016. ,
Dermatologie et infections sexuellement transmissibles, pp.269-280 ,
Le psoriasis : physiopathologie et immunogénétique, Pathol Biol, vol.62, issue.1, p.1023, 2014. ,
Pathogenesis and therapy of psoriasis, Nature, vol.445, p.866, 2007. ,
The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis, J Eur Acad Dermatol Venereol, vol.31, issue.10, p.161626, 2017. ,
, Encyclo Méd Chir, Dermatologie
Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis, J Manag Care Spec Pharm, vol.21, issue.10, p.87488, 2015. ,
DOI : 10.18553/jmcp.2015.21.10.874
Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies, J Eur Acad Dermatol Venereol JEADV, vol.27, issue.3, p.3646, 2013. ,
Psoriasis severity and the prevalence of major medical comorbidity: a population-based study, JAMA Dermatol, vol.149, issue.10, p.11739, 2013. ,
Psoriasis and comorbid diseases: Epidemiology, J Am Acad Dermatol, vol.76, issue.3, p.37790, 2017. ,
DOI : 10.1016/j.jaad.2016.07.064
URL : http://europepmc.org/articles/pmc5731650?pdf=render
Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies, J Am Heart Assoc, vol.2, issue.2, p.62, 2013. ,
Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis, J Invest Dermatol, vol.133, issue.10, p.23406, 2013. ,
Self-reported depression in psoriasis is associated with subclinical vascular diseases, Atherosclerosis, vol.251, p.21925, 2016. ,
The interface of depression and cardiovascular disease: therapeutic implications, Ann N Y Acad Sci, vol.1345, p.2535, 2015. ,
Dépression et risque cardiovasculaire, J Mal Vasc, vol.37, issue.2, p.523, 2012. ,
Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis, JAMA Dermatol, vol.149, issue.1, p.8491, 2013. ,
The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies, J Hypertens, vol.31, issue.3, p.43342, 2013. ,
The association between psoriasis and dyslipidaemia: a systematic review, Br J Dermatol, vol.168, issue.3, p.48695, 2013. ,
The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies, Nutr Diabetes, vol.2, p.54, 2012. ,
Is there a « metabolic-mood syndrome »? A review of the relationship between obesity and mood disorders, Neurosci Biobehav Rev, vol.52, p.89104, 2015. ,
Mood disorders and obesity: understanding inflammation as a pathophysiological nexus, Neuromolecular Med, vol.13, issue.2, p.93116, 2011. ,
The Epidemiology of Psoriatic Arthritis, Rheum Dis Clin North Am, vol.41, issue.4, p.54568, 2015. ,
Depression Is Associated with an Increased Risk of Psoriatic Arthritis among Patients with Psoriasis: A PopulationBased Study, J Invest Dermatol, vol.137, issue.4, p.82835, 2017. ,
The psychosocial burden of psoriatic arthritis, Semin Arthritis Rheum, vol.47, issue.3, p.35160, 2017. ,
Psoriasis and comorbid diseases: Implications for management, J Am Acad Dermatol, vol.76, issue.3, p.393403, 2017. ,
Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative, J Rheumatol, vol.42, issue.10, p.176780, 2015. ,
Major Depression and Psoriasis: A Psychodermatological Phenomenon, Skin Pharmacol Physiol, vol.29, issue.4, p.22030, 2016. ,
The stress of life-New focal point for understanding accidents, Ind Med Surg, vol.33, p.6215, 1964. ,
A Cross-sectional Study of Prevalence and Implications of Depression and Anxiety in Psoriasis, Indian J Psychol Med, vol.37, issue.4, p.43440, 2015. ,
Exploring the Physiological Link between Psoriasis and Mood Disorders, Dermatol Res Pract, p.409637, 2015. ,
, Atlas de démographie médicale en France, Conseil national de l'ordre des médecins, 2017.
Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression, J Eur Acad Dermatol Venereol JEADV, vol.31, issue.12, 2017. ,
, Skin Ther Lett, vol.22, issue.3, p.14, 2017.
Analysis of the Prevalence of Mental Disorders in Psoriasis: The Relevance of Psychiatric Assessment in Dermatology, Psychiatr Danub, vol.29, issue.4, p.4016, 2017. ,
The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis, J Eur Acad Dermatol Venereol JEADV, vol.31, issue.7, p.116875, 2017. ,
The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study, Arch Dermatol, vol.146, issue.8, p.8915, 2010. ,
The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis, J Invest Dermatol, vol.134, issue.6, p.154251, 2014. ,
Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting, Br J Dermatol, vol.176, issue.4, p.102834, 2017. ,
Risk of depression in women with psoriasis: a cohort study, Br J Dermatol, vol.173, issue.4, p.97580, 2015. ,
Interplay of Itch and Psyche in Psoriasis: An Update, Acta Derm Venereol, vol.96, issue.217, p.557, 2016. ,
Psoriasis and sleep disorders: A systematic review, Sleep Med Rev, vol.29, p.6375, 2016. ,
Sleep quality and other patientreported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial, Br J Dermatol, vol.167, issue.6, p.137481, 2012. ,
Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis, Dermatol Basel Switz, vol.212, issue.2, p.12836, 2006. ,
Depression and psoriasis, Ann Dermatol Venereol, vol.139, issue.2, pp.53-57, 2012. ,
Impact of Alexithymia and Disease Characteristics on Work Productivity and Activity In Psoriasis Patients With Short Disease Duration: Epidepso Multicentre Study, Value Health J Int Soc Pharmacoeconomics Outcomes Res, vol.18, issue.7, pp.425-426, 2015. ,
Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being, Br J Dermatol, vol.151, issue.6, p.121926, 2004. ,
Psoriasis and suicidality: A systematic review and metaanalysis, J Am Acad Dermatol, vol.77, issue.3, pp.425-440, 2017. ,
Risks of developing psychiatric disorders in pediatric patients with psoriasis, J Am Acad Dermatol, vol.67, issue.4, pp.651-657, 2012. ,
Psoriasis and smoking: a systematic review and meta-analysis, Br J Dermatol, vol.170, issue.2, p.30414, 2014. ,
Association entre tabagisme et état psychologique : impact de la consommation de tabac sur les suicides : la cohorte IPC, Rev Épidémiologie Santé Publique, vol.64, p.219, 2016. ,
Alcohol consumption and psoriasis: a systematic literature review, J Eur Acad Dermatol Venereol JEADV, vol.27, issue.3, p.305, 2013. ,
Addiction: an underestimated problem in psoriasis health care, J Eur Acad Dermatol Venereol JEADV, vol.31, issue.8, p.130815, 2017. ,
Comorbid addictions in bipolar disorder, L'Encephale, vol.34, pp.138-142, 2008. ,
Psychodermatological aspects of atopic dermatitis, Br J Dermatol, vol.170, p.3843, 2014. ,
The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries, J Invest Dermatol, vol.135, issue.4, p.98491, 2015. ,
Psychiatric morbidity in dermatological outpatients: an issue to be recognized, Br J Dermatol, vol.143, issue.5, p.98391, 2000. ,
, Ann Dermatol Vénéréologie, vol.135, issue.12, p.8635, 2008.
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR), J Am Acad Dermatol, vol.78, issue.1, p.7080, 2018. ,
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial, Lancet Lond Engl, vol.367, issue.9504, p.2935, 2006. ,
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderateto-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial, J Am Acad Dermatol, vol.63, issue.3, p.45765, 2010. ,
Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis, Br J Dermatol, vol.159, issue.3, p.70410, 2008. ,
Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review, J Eur Acad Dermatol Venereol JEADV, vol.29, issue.6, p.106370, 2015. ,
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial, J Am Acad Dermatol, vol.62, issue.5, p.8128, 2010. ,
Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies, Psychother Psychosom, vol.86, issue.5, p.2607, 2017. ,
Exacerbation of depression in a psoriatic arthritis patient possibly induced by secukinumab, Eur J Dermatol EJD, vol.26, issue.5, p.5067, 2016. ,
The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis, Int J Rheum Dis, vol.15, issue.2, p.1837, 2012. ,
, Commission de la transparence, Brodalumab, 2018.
Depression and acitretin: a true association or a class labeling?, J Drugs Dermatol JDD, vol.10, issue.4, p.40912, 2011. ,
Vitamin D, light and mental health, J Photochem Photobiol B, vol.101, issue.2, p.1429, 2010. ,
DOI : 10.1016/j.jphotobiol.2010.08.003
The effects of ultraviolet-A wavelengths in light therapy for seasonal depression, J Affect Disord, vol.24, issue.4, p.23743, 1992. ,
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ?156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2), J Am Acad Dermatol, vol.77, issue.2, pp.310-317, 2017. ,
, aprémilast) : nouvelles recommandations importantes concernant les idées et comportements suicidaires, 2016.